Methods of measuring adamts 13 activity
AssigneeBaxalta Incorporated
InventorsKatalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
Life of this patent
Estimating the term…
Abstract
The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
Claims32
A method for measuring a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity in a blood sample from a subject comprising the steps of:
- (a) measuring von Willebrand factor (VWF) cleavage fragments in the blood sample;
- (b) comparing the VWF cleavage fragments to a reference curve of different amounts of completely degraded VWF;
- and
- (c) quantifying an amount of ADAMTS13 activity based on the reference curve, wherein an amount of VWF cleavage fragments correlates with the amount of ADAMTS13 activity.
A method of assessing a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity in a subject comprising measuring total VWF and VWF cleavage fragments;
- comparing total VWF and VWF cleavage fragment level in a blood sample of the subject to a reference curve of increasingly degraded to completely degraded VWF;
- and assessing ADAMTS13 activity, wherein the VWF cleavage fragment level in the blood sample correlates to the ADAMTS13 activity deduced from the reference curve.
Dependencies are inferred from the claim text.